Follow-up to management strategies for candidates for protease inhibitors and requiring treatment for Mycobacterium tuberculosis.
Tseng
A
A
Toronto Hospital, University of Toronto, Department of Pharmacy.
Walmsley
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D004347:Drug Interactions; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D006801:Humans; D018579:Patient Selection; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012294:Rifamycins / Q000009:adverse effects*; D014376:Tuberculosis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D012294:Rifamycins; D054303:HIV Reverse Transcriptase